EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

miRNA as a Prognostic Marker in Small Lung Cell Carcinoma

Michał Bednarz iD, Aleksandra Osińska iD, Julia Durda iD, Milena Kędra iD, Michalina Boruch iD, Julia Gontarz iD, Alicja Petniak iD, Janusz Kocki iD, Paulina Gil-Kulik iD

Genes · 2025

DOI: 10.3390/genes16121465 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Genes, 2025. Verfasst von Michał Bednarz und 8 weiteren Autor:innen. Beteiligte Einrichtung: Student Scientific Society of Clinical Genetics, Medical University of Lublin, 11 Radziwillowska Str., 20-080 Lublin, Poland. Hauptthemen laut MEDLINE: MicroRNAs, Biomarkers, Tumor, Lung Neoplasms, Small Cell Lung Carcinoma. Die Arbeit nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Small-cell lung carcinoma (SCLC) is one of the most aggressive and therapeutically challenging malignancies. It is characterised by rapid progression, early metastasis and frequent relapse. Despite considerable advances in molecular oncology, effective biomarkers for prognosis and treatment response remain elusive. In this review, we summarise and discuss recent evidence on microRNAs (miRNAs) as central regulators of SCLC biology and their potential clinical applications. A narrative review of the literature was conducted. Search of PubMed and Scopus databases identified 14 miRNAs, including miR-7-5p, miR-22-3p, miR-134, miR-181b, miR-200b, miR-335, miR-335-5p, miR-495, miR-24-3p, miR-30a-5p, miR-30a-3p, miR-100, miR-1 and miR-494, which are linked to tumour progression, therapy resistance and metastasis. These molecules influence several signalling cascades, including PI3K/Akt, Hippo, TGF-β, PARP1-mediated DNA repair and autophagy. Their abnormal expression correlates with patient outcome and may enable plasma- or exosome-based non-invasive monitoring. In particular, strategies that restore or inhibit miRNA activity using mimics or antagomiRs show promise in improving drug sensitivity and complementing current treatment options. Overall, emerging evidence supports the integration of miRNA profiling into precision oncology for SCLC, with the aim of refining diagnosis, risk assessment and therapeutic decision-making.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MicroRNAsBiomarkers, TumorLung NeoplasmsSmall Cell Lung CarcinomaHumansPrognosisGene Expression Regulation, NeoplasticSignal Transduction

Stichwörter der Autor:innen

Hippo pathwayPI3K/AktSCLCbiomarkerchemoresistanceexosomesmiRNAmicroRNAprognosissmall-cell lung carcinoma

Substanzen

MicroRNAsBiomarkers, Tumor

Autor:innen und Institutionen

  • Student Scientific Society of Clinical Genetics, Medical University of Lublin, 11 Radziwillowska Str., 20-080 Lublin, Poland.
  • Department of Clinical Genetics, Medical University of Lublin, 11 Radziwillowska Str., 20-080 Lublin, Poland.

ORCID-Profile: Michał Bednarz, Aleksandra Osińska, Julia Durda, Milena Kędra, Michalina Boruch, Julia Gontarz, Alicja Petniak, Janusz Kocki, Paulina Gil-Kulik

Zitieren

APA

Bednarz, M., Osińska, A., Durda, J., Kędra, M., Boruch, M., Gontarz, J., Petniak, A., Kocki, J., & Gil-Kulik, P. (2025). miRNA as a Prognostic Marker in Small Lung Cell Carcinoma. Genes. https://doi.org/10.3390/genes16121465

Vancouver

Bednarz M, Osińska A, Durda J, Kędra M, Boruch M, Gontarz J, et al. miRNA as a Prognostic Marker in Small Lung Cell Carcinoma. Genes. 2025. doi:10.3390/genes16121465

BibTeX
@article{Bednarz2025,
  author = {Bednarz, Michał and Osińska, Aleksandra and Durda, Julia and Kędra, Milena and Boruch, Michalina and Gontarz, Julia and Petniak, Alicja and Kocki, Janusz and Gil-Kulik, Paulina},
  title = {miRNA as a Prognostic Marker in Small Lung Cell Carcinoma},
  journal = {Genes},
  year = {2025},
  doi = {10.3390/genes16121465}
}
Kostenlos starten →